Alogliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i), not only has anti-hyperglycemic effects, but can also inhibit the maintenance of AF induced by tachy-pacing, as shown in a recent animal study [13]. This evidence concerns the gene DPP4 and atrial fibrillation.